Navalign LLC’s Iovance Biotherapeutics IOVA Stock Holding History

Navalign LLC’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,000	Closed	-$2.73K	–	296
2025 Q4	$2.73K	Buy	+1,000	New	+$2.31K	﹤0.01%	415

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Navalign LLC's IOVA Position: Q1 2026 in Review

Navalign LLC sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 1,000 shares — an estimated $2.73K sold.

Navalign LLC first reported a position in IOVA in Q4 2025 and held it in 1 quarter. The position peaked at $2.73K in Q4 2025. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Navalign LLC reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
Navalign LLC sold 1,000 Iovance Biotherapeutics shares in Q1 2026, an estimated $2.73K.
Navalign LLC first reported a position in Iovance Biotherapeutics in Q4 2025 and held it in 1 quarter.
Navalign LLC's Iovance Biotherapeutics position peaked at $2.73K in Q4 2025.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Navalign LLC's 13F filing for Q1 2026, filed 29 Apr 2026.